Please ensure Javascript is enabled for purposes of website accessibility

Why Valeant Splurged $1 Billion on Sprout... and Why It's Worth It

By Eric Volkman - Sep 2, 2015 at 9:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The acquisitive pharmaceutical giant grabs the maker of the "female Viagra."

Last week, Valeant Pharmaceuticals (NYSE: VRX) said it reached an agreement to purchase privately-held Sprout Pharmaceuticals. The price is roughly $1 billion in cash, in addition to a share of future profits based on a set of milestones.

The reason for the buy is Sprout Pharmaceuticals' flagship product, flibanserin, which will be marketed in the U.S. as Addyi. The drug has been nicknamed "the female Viagra," alluding to the male erectile dysfunction treatment that's been a money-earner for Pfizer.

That nickname isn't quite accurate, as the drug works differently, and carries different risks than its masculine sort-of counterpart. Does that mean Valeant overpaid for its new asset?

Lifting libido, lifting profits?
The timing of the buy was certainly auspicious... for Sprout, that is. The deal went down just after the Food and Drug Administration approved Addyi for the treatment of hypoactive sexual desire disorder, or HSDD, in premenopausal women. It's the first and only medication of its kind given the green light by the FDA. No doubt that commanded a premium.

But there's a catch. Addyi isn't Viagra, which activates enzymes in order to improve blood flow to the necessary place. Instead, Sprout's medication targets the brain's neurotransmitters to increase libido.

At the moment, that seems to be a dicier proposition than increasing blood flow. It apparently produces side effects in some patients that include unconsciousness and low blood pressure, particularly when taking the drug in conjunction with alcohol.

As a result, unlike Viagra, it will only be available from certified medical professionals and pharmacies. It'll also carry a black-box warning on the label regarding those side effects.

Some estimates have it that around 10% of all women are afflicted by sexual desire disorder. That's a huge potential market to draw from, particularly considering that Addyi will be the only pharmaceutical available for treatment.

And it's coming soon. Valeant expects Addyi to be available in the U.S. starting in the fourth quarter of this year. With the company's global reach, it also plans to sell it abroad.

Given the fact that the drug is not only new, but the first of its kind, it's hard to say just how much revenue it stands to bring in. At least one estimate put potential peak sales at around $100 million per year, meaning Valeant will need more than a decade to reach breakeven.

I think that's very conservative. The potentially massive patient base for the drug is clearly underserved, and will likely not be dissuaded by the potential side effects. Most of these effects are connected with alcohol consumption, and I'd speculate that most women diagnosed with HSDD will happily forego drinking in favor of more satisfying sex.

A strong drug
A base price of $1 billion is far from cheap, even for a free-spending and acquisitive company like Valeant. But market-leading, impactful, and unique drugs don't hit the market every day -- particularly drugs that treat a condition millions of people struggle with.

In that light, I think buying Sprout was a good and opportunistic deal for Valeant. Yes, it's just a little pill, but it's packed with huge potential for its new owner.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$8.75 (20.36%) $1.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.